CENTURY THERAPEUTICS INC (IPSC)
Health Care · Cell therapy and regenerative medicine; allogeneic immunotherapy · NASDAQ
Century Therapeutics develops off-the-shelf allogeneic cell therapies using CRISPR-engineered iPSCs to treat autoimmune diseases and cancer.
What CENTURY THERAPEUTICS INC does
Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs) for autoimmune diseases and cancer. The company leverages proprietary CRISPR-based genetic engineering and its Allo-Evasion™ technology to create "off-the-shelf" iPSC-derived immune cells (T cells, NK cells) and beta islet cells that can be manufactured at scale and administered without patient-specific customization. Its lead programs include CNTY-101 (CAR-iNK cells in Phase 1/2 trials), CNTY-308 (CD19-targeted CAR-T cells in IND-enabling studies), and CNTY-813 (beta islet cells for type 1 diabetes in IND-enabling studies).
Themes: ["Cell therapy / regenerative medicine","Allogeneic cell-based immunotherapy","iPSC-derived cell therapies","CAR-T and CAR-NK cell therapies","Type 1 diabetes / beta islet cell therapy","B-cell-mediated autoimmune diseases","Off-the-shelf cell therapy","Gene editing / CRISPR"]
Fundamentals
- Price$2.31 as of 2026-07-09 close
- Market cap$417M as of 2026-07-10
- 1-year return+332.0% as of 2026-07-09 close
- Net margin-18.9% as of 2026-07-10
- ROE-53.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+175.9% as of 2026-07-10
- Revenue CAGR (3y)+175.9% SEC XBRL
- Beta1.57 as of 2026-07-10
Key risks (from latest filing)
["Early-stage clinical development: lead program (CNTY-101) in Phase 1/2 IST; CNTY-308 and CNTY-813 still in IND-enabling studies with no guarantee of regulatory approval or successful advancement to clinical trials","Novel technology risk: iPSC-derived allogeneic cell therapies represent a novel approach with limited clinical validation; regulatory pathways are uncertain and public scrutiny of cell-based immunotherapy could impact market acceptance","Manufacturing and scaling challenges: achieving consistent reproducibility, genomic stability, and cost-effective manufacturing at commercial scale; dependence on third-party suppliers and contract manufacturers"]
Competitors & peers
- Gilead Sciences / Kite Pharma (GILD)
- Juno Therapeutics (subsidiary of Celgene/Bristol Myers Squibb)
- Novartis CAR-T programs (NVS)
- Fate Therapeutics (FATE)
- Forty Seven Inc / Gilead (CD47 checkpoint)
- Vor Biopharma
- Sangamo Therapeutics (SGMO)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.